Zydus Lifesciences has informed that it enclosed press release ‘Zydus receives final approval from the USFDA for its NDA Zituvimet TM XR (sitagliptin and metformin hydrochloride) extended-release tablets’.
The above information is a part of company’s filings submitted to BSE.